摘要
近年来发现新生霉素能增强或降低某些抗癌药的细胞毒作用。但迄今用人肿瘤细胞进行研究报告很少。我们用两株人乳腺癌细胞株Ｔ４７Ｄ和ＭＣＦ７进行研究，同时还从这两株细胞培育出三株新生霉素耐药细胞株Ｔ４７Ｄ／ＮＯＶＯ１，ＭＣＦ７／ＮＯＶＯ７和ＭＣＦ７／ＮＯＶＯ１６，进行新生霉素的抗癌作用及调节机制探讨。结果表明新生霉素对两株乳腺癌细胞株有抑制作用，新生霉素对鬼臼乙叉甙的调节作用因细胞株而异。本文结果提示新生霉素对肿瘤化疗有较大意义。
Abstract There is an increasing interest in novobiocin as it is an modulator of some antitumor agents. Human breast cancer cell lines T47D and MCF7 were used in order to study the antitumor effect and the modulation mechanism of novobiocin. Novobiocin tolerant cell lines were made from T47D and MCF7, and were also used in this research. The results shew that novobiocin inhibited the cells of the breast cancer cell lines, and its effect was dose depandent. The modulation of novobiocin to etoposide (VP16) was different between T47D and MCF7. Novobiocin decreased the cytotoxicity of VP16 in T47D, but increased the cytotoxicity of VP16 in MCF7. The tolerant cell lines were tolerant to novobiocin, but their responds to combine drug treatment were similar to their parental lines.The results suggest that novobiocin is quite significant in clinical chemotherapy.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1995年第6期353-356,共4页
Cancer Research on Prevention and Treatment
